Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Comparative effectiveness of the sodiumglucose cotransporter 2 inhibitor empagliflozin versus other antihyperglycemics on risk of major adverse kidney events
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily licensed for the treatment of type 2 diabetes mellitus and, more recently, obesity
Yet beneath that success lies a fragile architecture built on convenience, marketing, and data liquidity
According to Katrina Ubell, MD, host of the podcast Weight Loss for Busy Physicians, it can be a "godsend" or some, "but it's not meant for someone who just has those last 20 pounds to lose." And as Amy Shah, MD, points out, the drugs aren't intended for people who can lose weight by adopting healthy lifestyle and diet measures
Yusta B, Baggio LL, Estall JL, et al
US$ 25.56
US$ 22.71
US$ 24.70
US$ 29.54
US$ 25.18
US$ 25.73
US$ 29.13
US$ 20.33
